melanoma

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

A EFFACER

Interferon alpha
EORTC18952 (Eggermont), 2005   ID IFN alpha-2b (I M)observationadjuvantnegative-16%-16%
Nordic IFN Trial, 2011     ID IFN alpha-2b (I M)observationadjuvantsuggesting-23%-9%
EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M)observationadjuvantsuggesting-13%-4%
EORTC18871/DKG 80-1 (Kleeberg), 2004   rIFN alpha-2bobservationadjuvantnegative4%-4%
ipilimumab
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive -24%-28%
nivolumab
CheckMate 238, 2017      NCTnivolumabipilimumabadjuvant adjuvant Low risk of bias conclusive-35%
pembrolizumab
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive -43%
trametinib + dabrafenib
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-53%-43%
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
vemurafenib
BRIM 8, 2018      NCTvemurafenibplaceboadjuvantsuggesting-35%-28%

All mechanism

Interferon alpha
EORTC18952 (Eggermont), 2005   ID IFN alpha-2b (I M)observationadjuvantnegative-16%-16%
Nordic IFN Trial, 2011     ID IFN alpha-2b (I M)observationadjuvantsuggesting-23%-9%
EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M)observationadjuvantsuggesting-13%-4%
EORTC18871/DKG 80-1 (Kleeberg), 2004   rIFN alpha-2bobservationadjuvantnegative4%-4%
ipilimumab
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive -24%-28%
nivolumab
CheckMate 238, 2017      NCTnivolumabipilimumabadjuvant adjuvant Low risk of bias conclusive-35%
pembrolizumab
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive -43%
trametinib + dabrafenib
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-53%-43%
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
vemurafenib
BRIM 8, 2018      NCTvemurafenibplaceboadjuvantsuggesting-35%-28%

B-Raf enzyme inhibitors

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias suggesting-46%
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenibsuggesting-61%
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectablesuggesting-25%-37%
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-53%-43%
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1Lsuggesting-44%-31%
vemurafenib
BRIM 8, 2018      NCTvemurafenibplaceboadjuvantsuggesting-35%-28%
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenibsuggesting-49%

combined BRAF-MEK inhibitors

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias suggesting-46%
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenibsuggesting-61%
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectablesuggesting-25%-37%
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-53%-43%
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1Lsuggesting-44%-31%
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenibsuggesting-49%

immune checkpoint inhibition

ipilimumab
Robert, 2011      NCTipilimumab + dacarbazinedacarbazine1L 1st line Low risk of bias conclusive-28%
Hodi (ipi + gp100), 2010      NCTipi + gp100gp1002L 2nd line Risk of bias suggesting-31%
Hodi (ipi alone), 2010      NCTipilimumab 3 mg/kggp1002L 2nd line Risk of bias suggesting-36%
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive -24%-28%
nivolumab
CheckMate 037 (Weber), 2015      NCTnivolumabchemotherapy2L, anti-CTLA-4 failure 2nd line Risk of bias suggesting
CheckMate 066 (Robert), 2015      NCTnivolumabdacarbazine1L 1st line Low risk of bias conclusive -57%-58%
CheckMate 238, 2017      NCTnivolumabipilimumabadjuvant adjuvant Low risk of bias conclusive-35%
CheckMate 067 (nivo vs ipi), 2015      NCTnivolumabipilimumab1L 1st line Low risk of bias conclusive-43%
CheckMate 067 (nivo + ipi vs ipi), 2015    NCTnivolumab + ipilimumabipilimumab1L 1st line Low risk of bias conclusive -58%
Postow, 2015      NCTnivolumab + ipilimumabipilimumab1L 1st line Exploratory -
CheckMate 067 (nivo + ipi vs nivo), 2015      NCTnivolumab + ipilimumabnivolumab1L 1st line Exploratory -
pembrolizumab
KEYNOTE 002 (10mg/kg Q3W), 2015      NCTpembrolizumab 10mg/kgchemotherapy2L 2nd line Exploratory suggesting-50%
KEYNOTE 002 (2mg/kg Q3W), 2015      NCTpembrolizumab 2mg/kgchemotherapy2L 2nd line Exploratory suggesting -43%
KEYNOTE-006 (every 2W), 2015      NCTpembrolizumab (every 2W)ipilimumab1L 1st line Risk of bias suggesting -42%-32%
KEYNOTE-006 (every 3W), 2015      NCTpembrolizumab (every 3W)ipilimumab1L 1st line Risk of bias suggesting -42%-32%
KEYNOTE-001, 2014      NCTpembrolizumab 2mg/kgpembrolizumab 10mg/kg2L 2nd line Exploratory negative-16%9%
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive -43%

interferon

Interferon alpha
EORTC18952 (Eggermont), 2005   ID IFN alpha-2b (I M)observationadjuvantnegative-16%-16%
Nordic IFN Trial, 2011     ID IFN alpha-2b (I M)observationadjuvantsuggesting-23%-9%
EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M)observationadjuvantsuggesting-13%-4%
EORTC18871/DKG 80-1 (Kleeberg), 2004   rIFN alpha-2bobservationadjuvantnegative4%-4%

MEK inhibitor

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias suggesting-46%
selumetinib
Kirkwood, 2012     selumetinibtemozolomide -
Kirkwood   selumetinibtemozolomide -
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenibsuggesting-61%
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectablesuggesting-25%-37%
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-53%-43%
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1Lsuggesting-44%-31%
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenibsuggesting-49%

Miscellaneous

Interferon alpha
EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M)observationadjuvantsuggesting-13%-4%
EORTC18871/DKG 80-1 stage III   rIFN alpha-2bobservation - 61%
ipilimumab
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive -24%-28%
nivolumab
CheckMate 238 subgroup IIIB-C   nivolumabipilimumabsuggesting-35%
pembrolizumab
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive -43%
trametinib + dabrafenib
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-53%-43%
vemurafenib
BRIM 8 (cohort IIIC)   vemurafenibplacebonegative-20%